Chimerix (NASDAQ:CMRX) Shares Gap Down to $6.43

Chimerix, Inc. (NASDAQ:CMRX)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $6.43, but opened at $6.05. Chimerix shares last traded at $6.24, with a volume of 5,203 shares trading hands.

A number of brokerages have recently commented on CMRX. Maxim Group reiterated a “buy” rating and set a $20.00 price target on shares of Chimerix in a report on Friday, August 6th. Zacks Investment Research lowered shares of Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, August 10th. Finally, HC Wainwright lifted their price target on shares of Chimerix from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, June 7th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Chimerix presently has a consensus rating of “Buy” and a consensus target price of $17.38.

The stock has a fifty day moving average of $6.88 and a 200 day moving average of $8.01. The firm has a market capitalization of $522.68 million, a P/E ratio of -3.36 and a beta of 1.59.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). Chimerix had a negative return on equity of 54.11% and a negative net margin of 3,035.43%. Research analysts expect that Chimerix, Inc. will post -0.61 earnings per share for the current fiscal year.

In related news, Director Fred A. Middleton purchased 6,950 shares of Chimerix stock in a transaction dated Monday, June 28th. The stock was bought at an average cost of $7.83 per share, for a total transaction of $54,418.50. Following the completion of the transaction, the director now owns 200,573 shares in the company, valued at $1,570,486.59. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in shares of Chimerix in the 1st quarter valued at about $166,000. Victory Capital Management Inc. bought a new stake in Chimerix in the 1st quarter worth about $118,000. Rhumbline Advisers increased its holdings in Chimerix by 2.7% in the 1st quarter. Rhumbline Advisers now owns 99,986 shares of the biopharmaceutical company’s stock worth $964,000 after buying an additional 2,625 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Chimerix by 1.8% during the 1st quarter. Alps Advisors Inc. now owns 113,320 shares of the biopharmaceutical company’s stock valued at $1,092,000 after purchasing an additional 1,950 shares during the period. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Chimerix by 335.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 43,374 shares of the biopharmaceutical company’s stock valued at $418,000 after purchasing an additional 33,402 shares during the period. Institutional investors and hedge funds own 52.96% of the company’s stock.

About Chimerix (NASDAQ:CMRX)

Chimerix, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Further Reading: What is the Nikkei 225 index?    

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.